Re: Farmas USA
ETRM
Léetelo bien, que el artículo no dice exactamente eso:
EnteroMedics (NASDAQ:ETRM) has received an average broker rating score of 1.50 (Buy) from the four analysts that cover the stock
Brokerages have set a twelve-month consensus target price of $3.81 for the company and are predicting that the company will post ($0.09) earnings per share for the current quarter, according to Zacks.
En cualquier caso, Zacks, puajs.
«Después de nada, o después de todo/ supe que todo no era más que nada.»